- recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis - EFC17559 / COAST1
This study is testing a new medicine, amlitelimab, for moderate-to-severe eczema in people aged 12 and older. It aims to see how well it clears up skin and reduces itching compared to a dummy treatment, given as an injection.
Poland · France · Greece - recruitingTherapeutic confirmatory (Phase III)
Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis on background topical corticosteroids - EFC17561 - SHORE
This study is testing a new medicine, amlitelimab, for people aged 12 and older with moderate-to-severe eczema that hasn't improved with other treatments. It aims to see if the medicine can reduce eczema symptoms and improve quality of life.
Italy · Germany · Czechia - recruitingTherapeutic exploratory (Phase II)
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.
This study is looking at a new medicine called GSK1070806 for people with moderate to severe eczema. It's a long-term study to see how safe and effective the medicine is over time, especially how it affects side effects and reduces eczema symptoms.
Czechia · Poland · Germany - recruitingHuman Pharmacology (Phase I)- Other
An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates
This study looks at how a new medicine, amlitelimab, affects other common medicines in the body. It's for adults with eczema and helps us understand how different drugs work together safely. This is an early-stage study to gather important information.
Germany · Bulgaria - recruitingTherapeutic exploratory (Phase II)
A Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of 3 subcutaneous dose regimens of lunsekimig (SAR443765) in adult participants with moderate to-severe atopic dermatitis
This study is testing a new medicine called lunsekimig for adults with moderate to severe eczema. We want to see how well it works to reduce eczema symptoms and if it's safe. Participants will receive either the new medicine or a dummy medicine.
Czechia · Poland - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis.
This study is testing a new medicine, amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It compares amlitelimab to a dummy medicine (placebo) to see if it improves eczema symptoms like itching and skin clearing.
Czechia · Portugal · Bulgaria - recruitingTherapeutic exploratory (Phase II)
A multinational, multicenter, double-blind, placebo-controlled phase 2 study to evaluate efficacy and safety of SAR444656 in adult participants with moderate to severe atopic dermatitis.
This study is testing a new medicine, SAR444656, for adults with moderate to severe eczema (atopic dermatitis). We want to see if it helps improve the skin and reduce symptoms like itching, and if it's safe to use.
Germany · Poland · Greece - recruitingPhase III and phase IV (Integrated)
A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis (Flex-Up)
This study looks at a medicine called Upadacitinib for adults with moderate to severe eczema. It wants to see how well it clears up skin symptoms and improves quality of life. The study compares different ways of giving the medicine.
Netherlands · Spain · Portugal - recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in adult participants with Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, GSK1070806, for adults with moderate to severe eczema (atopic dermatitis). We want to see how well it works, if it's safe, and what dose is best. Participants will get either the new medicine or a dummy medicine by injection.
Czechia · Germany · France - active not recruitingPHASE2, PHASE3
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
This study looks at a medicine called amlitelimab for moderate to severe eczema in people who've already tried it in other studies. We want to see how safe and effective it is over a long time, and if it continues to help.
United States · Argentina · Australia - active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
This study looks at a new medicine called amlitelimab for people aged 12 and over with moderate-to-severe eczema. These individuals haven't responded well to other common eczema treatments. Researchers want to see if amlitelimab is safe and helps improve their skin when used with their usual steroid creams.
United States · Argentina · Australia - active not recruiting
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
This study looks at children aged 0-11 with moderate to severe eczema (atopic dermatitis) that isn't well controlled with usual creams. Researchers want to understand their condition better, how it changes over time, and how current treatments are working in real life. It's an observational study, meaning no new treatments are being tested.
United States · Argentina · Australia - active not recruiting
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
This study looks at how Dupixent (a medicine for eczema) works for people with eczema in their everyday lives. Researchers want to understand who uses it, how they use it, and how effective and safe it is over time.
Argentina · Australia · Austria - active not recruiting
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
This study looks at how a medicine called Dupixent works for people with eczema (atopic dermatitis) in their everyday lives. We want to see how it's used, how well it helps, and if there are any side effects over time for people aged 12 and over.
United States · Canada - active not recruitingPHASE4
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
This study looks at how a medicine called dupilumab (Dupixent®) affects the skin barrier in children aged 6-14 with moderate to severe eczema over two years. It aims to understand if the medicine helps the skin stay healthy.
United States · United Kingdom - active not recruitingPHASE2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This study looks at a new treatment called amlitelimab for moderate to severe eczema in people aged 12 and older. It aims to understand its safety and how well it works over a long time. It involves regular visits and lasts several years.
United States · Argentina · Australia - active not recruitingPHASE2
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
This study is testing a new medicine called JNJ-95475939 for people with moderate to severe eczema (atopic dermatitis). Researchers want to see if it works better than a dummy medicine (placebo) to improve skin and reduce itching.
United States · Argentina · Brazil - active not recruitingPHASE3
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This study is testing a new medicine, Amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It's looking at how well different doses work and if they're safe, compared to stopping treatment.
United States · Argentina · Australia